← Leaderboards
Scott W Wong
Oregon Health And Science University
$37,618,864
Attributed
$37,618,864
Total exposure
50
Grants
34
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,618,864 · 50
By mechanism
R01$28,708,325 · 4
P51$5,656,948 · 42
U01$2,397,203 · 1
R21$826,388 · 2
R13$30,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaVirusInfectionVirus DiseasesViralResearch PersonnelHuman Herpesvirus 8RhadinovirusAnimal ModelPathogenesisIn VivoNonhuman PrimateAnimalsImmune ResponseHomologous GeneB-LymphocytesKaposi SarcomaLymphoproliferative DisordersMalignant NeoplasmsMediatingHyperplasiaRecombinantsIn VitroInsight
Grant awards (94)
Targeting CD180 to induce anti-KSHV response in nonhuman primates$1,184,569
U01 · FY2025 · CA · contact PI
Oral transmission of KSHV using rhesus macaque rhadinovirus model$805,884
R01 · FY2025 · CA · contact PI
Targeting CD180 to induce anti-KSHV response in nonhuman primates$1,212,634
U01 · FY2024 · CA · contact PI
Oral transmission of KSHV using rhesus macaque rhadinovirus model$791,132
R01 · FY2024 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$687,883
R01 · FY2024 · CA · contact PI
Oral transmission of KSHV using rhesus macaque rhadinovirus model$791,132
R01 · FY2023 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$688,251
R01 · FY2023 · CA · contact PI
Oral transmission of KSHV using rhesus macaque rhadinovirus model$791,132
R01 · FY2022 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$688,251
R01 · FY2022 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$688,251
R01 · FY2021 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$683,330
R01 · FY2020 · CA · contact PI
Investigating the development of AIDs and non-AIDS defining cancers in aged SIV-infected rhesus macaques.$581,403
R01 · FY2020 · CA · contact PI
Investigating the development of AIDs and non-AIDS defining cancers in aged SIV-infected rhesus macaques.$970,180
R01 · FY2019 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$678,245
R01 · FY2019 · CA · contact PI
Investigating the development of AIDs and non-AIDS defining cancers in aged SIV-infected rhesus macaques.$1,263,878
R01 · FY2018 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$727,306
R01 · FY2018 · CA · contact PI
Investigating the development of AIDs and non-AIDS defining cancers in aged SIV-infected rhesus macaques.$1,555,244
R01 · FY2017 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$794,238
R01 · FY2017 · CA · contact PI
Investigating the development of AIDs and non-AIDS defining cancers in aged SIV-infected rhesus macaques.$1,368,756
R01 · FY2016 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$748,902
R01 · FY2016 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$666,638
R01 · FY2015 · CA · contact PI
Induction of robust T cell response to RRV-LANA$190,313
R21 · FY2015 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$626,541
R01 · FY2014 · CA · contact PI
Induction of robust T cell response to RRV-LANA$228,375
R21 · FY2014 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$662,442
R01 · FY2013 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$689,049
R01 · FY2012 · CA · contact PI
Anti-viral IL6 approach to mitigate KSHV-related disease$523,041
R01 · FY2012 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$645,649
R01 · FY2011 · CA · contact PI
Anti-viral IL6 approach to mitigate KSHV-related disease$600,638
R01 · FY2011 · CA · contact PI
ANTI-VIRAL IL-6 APPROACH TO MITIGATE KSHV-RELATED DISEASE$243,563
P51 · FY2011 · RR · contact PI
RHESUS HHV8 HOMOLOGUE IN AIDS-RELATED MALIGNANCIES$243,563
P51 · FY2011 · RR · contact PI
Anti-viral IL6 approach to mitigate KSHV-related disease$642,809
R01 · FY2010 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$622,052
R01 · FY2010 · CA · contact PI
ANTI-VIRAL IL-6 APPROACH TO MITIGATE KSHV-RELATED DISEASE$190,131
P51 · FY2010 · RR · contact PI
RHESUS HHV8 HOMOLOGUE IN AIDS-RELATED MALIGNANCIES$190,131
P51 · FY2010 · RR · contact PI
TARGETING CELLULAR PROCESSES TO INHIBIT MONKEYPOX VIRUS INFECTION IN VIVO$47,603
P51 · FY2010 · RR · contact PI
IDENTIFYING TARGETS FOR THERAPEUTIC INTERVENTIONS USING PROTEOMIC TECHNOLOGY$47,603
P51 · FY2010 · RR · contact PI
GAMMA-2 HERPESVIRUS-ASSOCIATED JAPANESE MACAQUE ENCEPHALOMYELITIS$47,603
P51 · FY2010 · RR · contact PI
Anti-viral IL6 approach to mitigate KSHV-related disease$680,879
R01 · FY2009 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$611,550
R01 · FY2009 · CA · contact PI
RHESUS HHV8 HOMOLOGUE IN AIDS-RELATED MALIGNANCIES$206,673
P51 · FY2009 · RR · contact PI
EXPANDING VIROLOGY IN THE NON-HUMAN PRIMATE$103,268
P51 · FY2009 · RR · contact PI
IDENTIFYING TARGETS FOR THERAPEUTIC INTERVENTIONS USING PROTEOMIC TECHNOLOGY$80,343
P51 · FY2009 · RR · contact PI
GAMMA-2 HERPESVIRUS-ASSOCIATED JAPANESE MACAQUE ENCEPHALOMYELITIS$60,393
P51 · FY2009 · RR · contact PI
VALIDATING VIL-6 AS A TARGET FOR KSHV-ASSOCIATED DISEASE$51,566
P51 · FY2009 · RR · contact PI
TARGETING CELLULAR PROCESSES TO INHIBIT MONKEYPOX VIRUS INFECTION IN VIVO$51,566
P51 · FY2009 · RR · contact PI
Anti-viral IL6 approach to mitigate KSHV-related disease$643,832
R01 · FY2008 · CA · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$595,989
R01 · FY2008 · CA · contact PI
RHESUS HHV8 HOMOLOGUE IN AIDS-RELATED MALIGNANCIES$176,141
P51 · FY2008 · RR · contact PI
EXPANDING VIROLOGY IN THE NON-HUMAN PRIMATE$176,141
P51 · FY2008 · RR · contact PI
IDENTIFYING TARGETS FOR THERAPEUTIC INTERVENTIONS USING PROTEOMIC TECHNOLOGY$55,512
P51 · FY2008 · RR · contact PI
VALIDATING VIL-6 AS A TARGET FOR KSHV-ASSOCIATED DISEASE$35,312
P51 · FY2008 · RR · contact PI
TARGETING CELLULAR PROCESSES TO INHIBIT MONKEYPOX VIRUS INFECTION IN VIVO$11,144
P51 · FY2008 · RR · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$698,374
R01 · FY2007 · CA · contact PI
RHESUS HHV8 HOMOLOGUE IN AIDS-RELATED MALIGNANCIES$338,908
P51 · FY2007 · RR · contact PI
VALIDATING VIL-6 AS A TARGET FOR KSHV-ASSOCIATED DISEASE$225,890
P51 · FY2007 · RR · contact PI
TARGETING CELLULAR PROCESSES TO INHIBIT MONKEYPOX VIRUS INFECTION IN VIVO$75,850
P51 · FY2007 · RR · contact PI
EXPANDING VIROLOGY IN THE NON-HUMAN PRIMATE$56,512
P51 · FY2007 · RR · contact PI
10th International KSHV and Related Agents Workshop$30,000
R13 · FY2007 · CA · contact PI
IDENTIFYING TARGETS FOR THERAPEUTIC INTERVENTIONS USING PROTEOMIC TECHNOLOGY$14,673
P51 · FY2007 · RR · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$640,999
R01 · FY2006 · CA · contact PI
EXPANDING VIROLOGY IN THE NON-HUMAN PRIMATE$262,324
P51 · FY2006 · RR · contact PI
VALIDATING VIL-6 AS A TARGET FOR KSHV-ASSOCIATED DISEASE$131,162
P51 · FY2006 · RR · contact PI
RHESUS HHV8 HOMOLOGUE IN AIDS-RELATED MALIGNANCIES$131,162
P51 · FY2006 · RR · contact PI
IDENTIFYING TARGETS FOR THERAPEUTIC INTERVENTIONS USING PROTEOMIC TECHNOLOGY$76,828
P51 · FY2006 · RR · contact PI
Rhesus HHV-8 homologue in AIDS-related malignancies$539,337
R01 · FY2005 · CA
Validating VIL-6 as a target for KSHV-associated disease$203,850
R21 · FY2005 · CA
EXPANDING VIROLOGY IN THE NON-HUMAN PRIMATE$190,772
P51 · FY2005 · RR
RHESUS HHV8 HOMOLOGUE IN AIDS-RELATED MALIGNANCIES$94,798
P51 · FY2005 · RR
VALIDATING VIL-6 AS A TARGET FOR KSHV-ASSOCIATED DISEASE$94,156
P51 · FY2005 · RR
IDENTIFYING TARGETS FOR THERAPEUTIC INTERVENTIONS USING PROTEOMIC TECHNOLOGY$74,664
P51 · FY2005 · RR
RHESUS HHV 8 HOMOLOGUE IN AIDS RELATED MALIGNACIES$716,522
R01 · FY2004 · CA
Validating VIL-6 as a target for KSHV-associated disease$203,850
R21 · FY2004 · CA
RHESUS HHV8 HOMOLOGUE IN AIDS-RELATED MALIGNANCIES$105,323
P51 · FY2004 · RR
RHESUS CYTOMEGALOVIRUS ASSOCIATED DISEASE IN THE IMMUNODEFICIENT MACAQUE$52,662
P51 · FY2004 · RR
MOLECULAR BASIS FOR LYMPHOCRYPTOVIRUS-ASSOCIATED DISEASE IN NONHUMAN PRIMATES$52,662
P51 · FY2004 · RR
RHESUS HHV 8 HOMOLOGUE IN AIDS RELATED MALIGNACIES$672,498
R01 · FY2003 · CA
RHESUS HHV 8 HOMOLOGUE IN AIDS RELATED MALIGNACIES$652,913
R01 · FY2002 · CA
RHESUS HHV8 HOMOLOGUE IN AIDS RELATED MALIGNANCIES$111,112
P51 · FY2002 · RR
NONHUMAN PRIMATE MODEL OF CYTOMEGALOVIRUS ASSOCIATED DISEASE$111,112
P51 · FY2002 · RR
NONHUMAN PRIMATE MODEL OF CYTOMEGALOVIRUS (CMV) RETINITIS$111,112
P51 · FY2002 · RR
NONINFECTIOUS SIV AS VACCINE MODEL$111,112
P51 · FY2002 · RR
RHESUS HHV 8 HOMOLOGUE IN AIDS RELATED MALIGNACIES$633,895
R01 · FY2001 · CA
NONHUMAN PRIMATE MODEL OF CYTOMEGALOVIRUS ASSOCIATED DISEASE$111,112
P51 · FY2001 · RR
NONHUMAN PRIMATE MODEL OF CYTOMEGALOVIRUS (CMV) RETINITIS$111,112
P51 · FY2001 · RR
RHESUS HHV8 HOMOLOGUE IN AIDS RELATED MALIGNANCIES$111,112
P51 · FY2001 · RR
NONINFECTIOUS SIV AS VACCINE MODEL$111,112
P51 · FY2001 · RR
RHESUS HHV 8 HOMOLOGUE IN AIDS RELATED MALIGNACIES$639,280
R01 · FY2000 · CA
NONINFECTIOUS SIV AS VACCINE MODEL$128,575
P51 · FY2000 · RR
RHESUS HHV8 HOMOLOGUE IN AIDS RELATED MALIGNANCIES$128,575
P51 · FY2000 · RR
NONHUMAN PRIMATE MODEL OF CYTOMEGALOVIRUS (CMV) RETINITIS$128,575
P51 · FY2000 · RR
DEVELOPMENT OF SCREENING METHOD FOR SIMIAN FOAMY VIRUS$128,575
P51 · FY2000 · RR
DEVELOPMENT OF PATHOGENIC MOLECULAR CLONE OF SHIVKU 2$128,575
P51 · FY2000 · RR
RHESUS HHV8 HOMOLOGUE IL 6 IN B CELL HYPERPLASIA$128,575
P51 · FY2000 · RR